Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q96NU7: Variant p.Ser3Gly

Probable imidazolonepropionase
Gene: AMDHD1
Feedback?
Variant information Variant position: help 3 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Serine (S) to Glycine (G) at position 3 (S3G, p.Ser3Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 3 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 426 The length of the canonical sequence.
Location on the sequence: help MA S GHSLLLENAQQVVLVCARGE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         MASGHSLLLENAQQVVLVCARGE

Mouse                         MTSSHRLLLENAQQVVLVCARGE

Bovine                        MAGGHRLLLENARQVVLVCARGE

Xenopus laevis                MASKFRLLLENAEQIVVVCTKEE

Xenopus tropicalis            MACKFRLLLENAEQIVVVCSKEE

Zebrafish                     SANSFKLLVKNATQLVLVCRNGE

Slime mold                    MGFDFKLKISNASQLVVI-SKGK

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 426 Probable imidazolonepropionase



Literature citations
Complete sequencing and characterization of 21,243 full-length human cDNAs.
Ota T.; Suzuki Y.; Nishikawa T.; Otsuki T.; Sugiyama T.; Irie R.; Wakamatsu A.; Hayashi K.; Sato H.; Nagai K.; Kimura K.; Makita H.; Sekine M.; Obayashi M.; Nishi T.; Shibahara T.; Tanaka T.; Ishii S.; Yamamoto J.; Saito K.; Kawai Y.; Isono Y.; Nakamura Y.; Nagahari K.; Murakami K.; Yasuda T.; Iwayanagi T.; Wagatsuma M.; Shiratori A.; Sudo H.; Hosoiri T.; Kaku Y.; Kodaira H.; Kondo H.; Sugawara M.; Takahashi M.; Kanda K.; Yokoi T.; Furuya T.; Kikkawa E.; Omura Y.; Abe K.; Kamihara K.; Katsuta N.; Sato K.; Tanikawa M.; Yamazaki M.; Ninomiya K.; Ishibashi T.; Yamashita H.; Murakawa K.; Fujimori K.; Tanai H.; Kimata M.; Watanabe M.; Hiraoka S.; Chiba Y.; Ishida S.; Ono Y.; Takiguchi S.; Watanabe S.; Yosida M.; Hotuta T.; Kusano J.; Kanehori K.; Takahashi-Fujii A.; Hara H.; Tanase T.-O.; Nomura Y.; Togiya S.; Komai F.; Hara R.; Takeuchi K.; Arita M.; Imose N.; Musashino K.; Yuuki H.; Oshima A.; Sasaki N.; Aotsuka S.; Yoshikawa Y.; Matsunawa H.; Ichihara T.; Shiohata N.; Sano S.; Moriya S.; Momiyama H.; Satoh N.; Takami S.; Terashima Y.; Suzuki O.; Nakagawa S.; Senoh A.; Mizoguchi H.; Goto Y.; Shimizu F.; Wakebe H.; Hishigaki H.; Watanabe T.; Sugiyama A.; Takemoto M.; Kawakami B.; Yamazaki M.; Watanabe K.; Kumagai A.; Itakura S.; Fukuzumi Y.; Fujimori Y.; Komiyama M.; Tashiro H.; Tanigami A.; Fujiwara T.; Ono T.; Yamada K.; Fujii Y.; Ozaki K.; Hirao M.; Ohmori Y.; Kawabata A.; Hikiji T.; Kobatake N.; Inagaki H.; Ikema Y.; Okamoto S.; Okitani R.; Kawakami T.; Noguchi S.; Itoh T.; Shigeta K.; Senba T.; Matsumura K.; Nakajima Y.; Mizuno T.; Morinaga M.; Sasaki M.; Togashi T.; Oyama M.; Hata H.; Watanabe M.; Komatsu T.; Mizushima-Sugano J.; Satoh T.; Shirai Y.; Takahashi Y.; Nakagawa K.; Okumura K.; Nagase T.; Nomura N.; Kikuchi H.; Masuho Y.; Yamashita R.; Nakai K.; Yada T.; Nakamura Y.; Ohara O.; Isogai T.; Sugano S.;
Nat. Genet. 36:40-45(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT GLY-3; Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas.
Yamada S.; Ohira M.; Horie H.; Ando K.; Takayasu H.; Suzuki Y.; Sugano S.; Hirata T.; Goto T.; Matsunaga T.; Hiyama E.; Hayashi Y.; Ando H.; Suita S.; Kaneko M.; Sasaki F.; Hashizume K.; Ohnuma N.; Nakagawara A.;
Oncogene 23:5901-5911(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT GLY-3; The finished DNA sequence of human chromosome 12.
Scherer S.E.; Muzny D.M.; Buhay C.J.; Chen R.; Cree A.; Ding Y.; Dugan-Rocha S.; Gill R.; Gunaratne P.; Harris R.A.; Hawes A.C.; Hernandez J.; Hodgson A.V.; Hume J.; Jackson A.; Khan Z.M.; Kovar-Smith C.; Lewis L.R.; Lozado R.J.; Metzker M.L.; Milosavljevic A.; Miner G.R.; Montgomery K.T.; Morgan M.B.; Nazareth L.V.; Scott G.; Sodergren E.; Song X.-Z.; Steffen D.; Lovering R.C.; Wheeler D.A.; Worley K.C.; Yuan Y.; Zhang Z.; Adams C.Q.; Ansari-Lari M.A.; Ayele M.; Brown M.J.; Chen G.; Chen Z.; Clerc-Blankenburg K.P.; Davis C.; Delgado O.; Dinh H.H.; Draper H.; Gonzalez-Garay M.L.; Havlak P.; Jackson L.R.; Jacob L.S.; Kelly S.H.; Li L.; Li Z.; Liu J.; Liu W.; Lu J.; Maheshwari M.; Nguyen B.-V.; Okwuonu G.O.; Pasternak S.; Perez L.M.; Plopper F.J.H.; Santibanez J.; Shen H.; Tabor P.E.; Verduzco D.; Waldron L.; Wang Q.; Williams G.A.; Zhang J.; Zhou J.; Allen C.C.; Amin A.G.; Anyalebechi V.; Bailey M.; Barbaria J.A.; Bimage K.E.; Bryant N.P.; Burch P.E.; Burkett C.E.; Burrell K.L.; Calderon E.; Cardenas V.; Carter K.; Casias K.; Cavazos I.; Cavazos S.R.; Ceasar H.; Chacko J.; Chan S.N.; Chavez D.; Christopoulos C.; Chu J.; Cockrell R.; Cox C.D.; Dang M.; Dathorne S.R.; David R.; Davis C.M.; Davy-Carroll L.; Deshazo D.R.; Donlin J.E.; D'Souza L.; Eaves K.A.; Egan A.; Emery-Cohen A.J.; Escotto M.; Flagg N.; Forbes L.D.; Gabisi A.M.; Garza M.; Hamilton C.; Henderson N.; Hernandez O.; Hines S.; Hogues M.E.; Huang M.; Idlebird D.G.; Johnson R.; Jolivet A.; Jones S.; Kagan R.; King L.M.; Leal B.; Lebow H.; Lee S.; LeVan J.M.; Lewis L.C.; London P.; Lorensuhewa L.M.; Loulseged H.; Lovett D.A.; Lucier A.; Lucier R.L.; Ma J.; Madu R.C.; Mapua P.; Martindale A.D.; Martinez E.; Massey E.; Mawhiney S.; Meador M.G.; Mendez S.; Mercado C.; Mercado I.C.; Merritt C.E.; Miner Z.L.; Minja E.; Mitchell T.; Mohabbat F.; Mohabbat K.; Montgomery B.; Moore N.; Morris S.; Munidasa M.; Ngo R.N.; Nguyen N.B.; Nickerson E.; Nwaokelemeh O.O.; Nwokenkwo S.; Obregon M.; Oguh M.; Oragunye N.; Oviedo R.J.; Parish B.J.; Parker D.N.; Parrish J.; Parks K.L.; Paul H.A.; Payton B.A.; Perez A.; Perrin W.; Pickens A.; Primus E.L.; Pu L.-L.; Puazo M.; Quiles M.M.; Quiroz J.B.; Rabata D.; Reeves K.; Ruiz S.J.; Shao H.; Sisson I.; Sonaike T.; Sorelle R.P.; Sutton A.E.; Svatek A.F.; Svetz L.A.; Tamerisa K.S.; Taylor T.R.; Teague B.; Thomas N.; Thorn R.D.; Trejos Z.Y.; Trevino B.K.; Ukegbu O.N.; Urban J.B.; Vasquez L.I.; Vera V.A.; Villasana D.M.; Wang L.; Ward-Moore S.; Warren J.T.; Wei X.; White F.; Williamson A.L.; Wleczyk R.; Wooden H.S.; Wooden S.H.; Yen J.; Yoon L.; Yoon V.; Zorrilla S.E.; Nelson D.; Kucherlapati R.; Weinstock G.; Gibbs R.A.;
Nature 440:346-351(2006)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANT GLY-3; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT GLY-3;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.